Phase III Trial Shows Safe Co-Administration of PCV15 and DTaP in Infants
A phase III trial demonstrated that co-administration of PCV15 and DTaP in infants is safe and immunogenic, with no significant adverse interactions.
Asset / Drug
Drug and asset intelligence for PCV15 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Vaccines
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.